Primary Central Nervous System Lymphoma - 27 Studies Found
Not yet recruiting |
: Ketogenic Diet Adjunctive to HD-MTX Chemotherapy for Primary Central Nervous System Lymphoma : Primary Central Nervous System Lymphoma : 2016-11-29 :
|
Recruiting |
: MT-R Followed by Autologous Stem Cells Transplantation in Newly-diagnosed Primary Central Nervous System Lymphoma : Primary Central Nervous System Lymphoma : 2015-03-01 : Drug: R-MT followed by auto-HSCT Four cycles of Induction therapy: Rituximab 375mg/m2 d1; Methotrexate 3 |
Recruiting |
: Study on Pembrolizumab for Recurrent Primary Central Nervous System Lymphoma (PCNSL) : Primary Central Nervous System Lymphoma : 2016-05-17 : Drug: pembrolizumab Pembrolizumab 200 mg every 3 weeks |
Withdrawn |
: Antineoplaston Therapy in Treating Patients With Primary Central Nervous System Lymphoma : Primary Central Nervous System Lymphoma : 1999-11-01 :
|
Withdrawn |
: a Phase II Study in Primary Central Nervous System Lymphoma : Primary Central Nervous System Lymphoma : 2007-04-02 :
|
Recruiting |
: PQR309 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma : Primary Central Nervous System Lymphoma : 2016-01-07 : Drug: PQR309 Oral PQR309, 80mg or 60mg daily or intermittent dosing |
Not yet recruiting |
: PQR309 in Phase 2 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma : Primary Central Nervous System Lymphoma : 2017-04-10 : Drug: PQR309 Oral PQR309, 80mg or 60mg daily or intermittent dosing |
Withdrawn |
: Study of Pemetrexed to Treat Recurrent or Progressive Primary Central Nervous System Lymphoma : Primary Central Nervous System Lymphoma : 2008-07-03 : Drug: Pemetrexed 500 mg/m2 given as an injection into a vein over 10 minutes once every 21 days until pr |
Completed |
: Idarubicin Based Combined Modality Therapy in Primary CNS Lymphoma : Primary Central Nervous System Lymphoma : 2005-09-13 :
|
Recruiting |
: Temozolomide in Treatment of Patients With Primary Central Nervous System Lymphoma : Primary CNS Lymphoma : 2016-10-13 :
|